**Articles**

**\[¹⁷⁷Lu\]Lu-DOTA-TATE plus long-acting octreotide versus **

**high-dose long-acting octreotide for the treatment of newly** **diagnosed, advanced grade 2–3, well-differentiated, **

**gastroenteropancreatic neuroendocrine tumours **

**\(NETTER-2\): an open-label, randomised, phase 3 study**

*Simron Singh, Daniel Halperin, Sten Myrehaug, Ken Herrmann, Marianne Pavel, Pamela L Kunz, Beth Chasen, Salvatore Tafuto, Secondo Lastoria,* *Jaume Capdevila, Amparo García-Burillo, Do-Youn Oh, Changhoon Yoo, Thorvardur R Halfdanarson, Stephen Falk, Ilya Folitar, Yufen Zhang,* *Paola Aimone, Wouter W de Herder, Diego Ferone, on behalf of all the NETTER-2 Trial Investigators\**

**Summary**

**Background There are currently no standard first-line treatment options for patients with higher grade 2–3, well- *Lancet***** 2024; 403: 2807–17 **

**differentiated, advanced, gastroenteropancreatic neuroendocrine tumours. We aimed to investigate the efficacy and **Published **Online** **safety of first-line \[¹⁷⁷Lu\]Lu-DOTA-TATE \(¹⁷⁷Lu-Dotatate\) treatment. **

June 5, 2024 

https://doi.org/10.1016/ 

**Methods **

S0140-6736\(24\)00701-3

**NETTER-2 was an open-label, randomised, parallel-group, superiority, phase 3 trial. We enrolled patients** **\(aged ≥15 years\) with newly diagnosed higher grade 2 \(Ki67 ≥10% and ≤20%\) and grade 3 \(Ki67 >20% and ≤55%\), **See **Comment** page 2759

**somatostatin receptor-positive \(in all target lesions\), advanced gastroenteropancreatic neuroendocrine tumours from **\*Investigators are listed in appendix 1 \(p 2\)

**45 centres across nine countries in North America, Europe, and Asia. We used interactive response technologies to University of Toronto,** **randomly assign \(2:1\) patients to receive four cycles \(cycle interval was 8 weeks ± 1 week\) of intravenous ¹⁷⁷Lu-Dotatate Sunnybrook Odette Cancer** **plus intramuscular octreotide 30 mg long-acting repeatable \(LAR\) then octreotide 30 mg LAR every 4 weeks Centre, Toronto, ON, Canada** **\(¹⁷⁷Lu-Dotatate group\) or high-dose octreotide 60 mg LAR every 4 weeks \(control group\), stratified by neuroendocrine **\(S Singh MD, S Myrehaug MD\)**;** **tumour grade \(2 *vs***** 3\) and origin \(pancreas *vs**** ***other\). Tumour assessments were done at baseline, week 16, and MD Anderson Cancer Center,** **Houston, TX, USA** 

**week 24, and then every 12 weeks until disease progression or death. The primary endpoint was progression-free **\(D Halperin MD, B Chasen MD\)**;** **survival by blinded, independent, central radiology assessment. We did the primary analysis at 101 progression-free Department of Nuclear** **survival events as the final progression-free survival analysis. NETTER-2 is registered with ClinicalTrials.gov, Medicine, University of** **NCT03972488, and is active and not recruiting. **

**Duisburg-Essen, and German **

**Cancer Consortium **

**\(DKTK\)-University Hospital **

**Findings Between Jan 22, 2020, and Oct 13, 2022, we screened 261 patients, 35 \(13%\) of whom were excluded. We Essen, Essen, Germany** **randomly assigned 226 \(87%\) patients \(121 \[54%\] male and 105 \[46%\] female\) to the ¹⁷⁷Lu-Dotatate group \(n=151 \[67%\]\) **\(K Herrmann MD\)**; ** **National** **and control group \(n=75 \[33%\]\). Median progression-free survival was 8·5 months \(95% CI 7·7–13·8\) in the control Center for Tumor Diseases** **\(NCT\), NCT West, Heidelberg, **

**group and 22·8 months \(19·4–not estimated\) in the ¹⁷⁷Lu-Dotatate group \(stratified hazard ratio 0·276 \[0·182–0·418\]; Germany** \(K Herrmann\)**;** **p<0·0001\). During the treatment period, adverse events \(of any grade\) occurred in 136 \(93%\) of 147 treated patients in Department of Medicine 1,** **the ¹⁷⁷Lu-Dotatate group and 69 \(95%\) of 73 treated patients in the control group. There were no study drug-related Uniklinikum Erlangen, and** **deaths during the treatment period. **

**Comprehensive Cancer Center **

**Erlangen-EMN, Friedrich-**

**Alexander-Universität **

**Interpretation First-line ¹⁷⁷Lu-Dotatate plus octreotide LAR significantly extended median progression-free survival Erlangen-Nürnberg, Erlangen,** **\(by 14 months\) in patients with grade 2 or 3 advanced gastroenteropancreatic neuroendocrine tumours. ¹⁷⁷Lu-Dotatate Germany** \(Prof M Pavel MD\)**;** **should be considered a new standard of care in first-line therapy in this population. **

**Yale School of Medicine and **

**Yale Cancer Center, Yale **

**University, New Haven, CT, **

**Funding Advanced Accelerator Applications, a Novartis Company. **

**USA** \(P L Kunz MD\)**; Sarcoma **

**and Rare Tumors Unit, Istituto **

**Copyright © 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar Nazionale Tumori IRCCS,** **Fondazione G. Pascale, Naples, **

**technologies. **

**Italy** \(S Tafuto MD\)**; ** **Division of **

**Nuclear Medicine, Istituto **

**Introduction**

decades.3 The groundbreaking phase 3 NETTER-1 trial **Nazionale Tumori IRCCS,** **Fondazione G Pascale, Naples, **

Radioligand therapy delivers cytotoxic radiation directly established the efficacy and safety of ¹⁷⁷Lu-Dotatate plus **Italy **\(S Lastoria MD\)**; ** **Vall** to the tumour and, unlike most other systemic therapies, octreotide 30 mg long-acting repeatable \(LAR\) for the **d’Hebron University Hospital,** adverse events are generally minimal.1 \[¹⁷⁷Lu\]Lu-DOTA-treatment of patients with advanced somatostatin **Vall d’Hebron Institute of** TATE \(¹⁷⁷Lu-Dotatate\) is a ¹⁷⁷Lu-labelled somatostatin receptor-positive grade 1 or grade 2 midgut NETs who **Oncology \(VHIO\), Barcelona,** **Spain** \(J Capdevila MD, 

analogue that binds to somatostatin receptors,2 which are had progressed on somatostatin analogues.4,5

A García-Burillo MD\)**; Seoul **

highly expressed in neuroendocrine tumours \(NETs\) and 

In the first-line advanced or metastatic setting, **National University Hospital,** have been used diagnostically and therapeutically for international guidelines recommend somatostatin **Cancer Research Institute,** www.thelancet.com * ***Vol 403 June 29, 2024 **

**2807**

**Articles**

**Seoul National University **

**College of Medicine, Integrated **

**Research in context**

**Major in Innovative Medical **

**Science, Seoul National **

**Evidence before this study**

**Added value of this study**

**University Graduate School, **

In 2017, grade 3 well-differentiated neuroendocrine tumours 

NETTER-2 is the first randomised trial in any metastatic solid **Seoul, South Korea** 

were formally classified as a separate entity from the poorly 

tumour to investigate a radioligand therapy in a first-line 

\(D-Y Oh MD\)**; ** **Asan Medical **

differentiated neuroendocrine carcinomas by WHO. Following 

metastatic setting. Among patients with higher grade 2 

**Center, University of Ulsan **

**College of Medicine, Seoul, **

the phase 3 PROMID and CLARINET studies, somatostatin 

\(Ki67 ≥10% and ≤20%\) and grade 3 \(Ki67 >20% and ≤55%\) 

**South Korea** \(C Yoo MD\)**; ** **Mayo **

analogues are the recognised first-line treatment for advanced well-differentiated gastroenteropancreatic neuroendocrine 

**Clinic, Rochester, MN, USA** 

grade 1–2 \(Ki67 <10%\) gastroenteropancreatic neuroendocrine tumours, ¹⁷⁷Lu-Dotatate plus octreotide 30 mg LAR showed 

\(T R Halfdanarson MD\)**; ** **Bristol **

tumours and the role of platinum-based chemotherapy is 

a significant progression-free survival benefit versus high-dose **Haematology and Oncology **

**Centre, University Hospitals **

generally accepted for neuroendocrine carcinomas, but there 

octreotide 60 mg LAR \(median progression-free survival 

**Bristol NHS Foundation Trust, **

are limited robust data to support first-line treatment options 22·8 months *vs* 8·5 months\), with a high and durable response **Bristol, UK **\(S Falk MD\)**; Novartis **

for patients with advanced higher grade 2 \(Ki67 ≥10% and 

\(overall response rate 43%; median duration of response 

**Pharma AG, Basel, Switzerland** 

≤20%\) and grade 3 \(Ki67 >20% and ≤55%\) well-differentiated 

23·3 months\) without deterioration in quality of life. Our results \(I Folitar MD, P Aimone MD\)**; ** 

**Novartis Pharmaceuticals Corp, **

gastroenteropancreatic neuroendocrine tumours. To our 

will help to fill the evidence gap for high-grade 

**East Hanover, NJ, USA **

knowledge, at the time of the NETTER-2 study design, no 

gastroenteropancreatic neuroendocrine tumours that has been 

\(Y Zhang PhD\)**; ** **Erasmus MC and **

randomised phase 3 studies had been done in this population 

highlighted in treatment guidelines and aid treatment decision **Erasmus MC Cancer Institute, **

of patients with newly diagnosed, advanced or metastatic 

making for these patients who currently have a worse 

**Rotterdam, Netherlands** 

\(W W de Herder MD\)**; ** 

disease. This represents an unmet need and has been identified prognosis compared with patients with lower-grade disease. 

**Endocrinology, IRCCS **

as an evidence gap in treatment guidelines. The pivotal, 

**Policlinico San Martino and **

**Implications of all the available evidence**

phase 3, NETTER-1 study showed that treatment with the 

**DiMI, University of Genova, **

NETTER-2 provides the first robust, randomised, phase 3 data 

**Genoa, Italy** \(D Ferone MD\)

radioligand therapy \[¹⁷⁷Lu\]Lu-DOTA-TATE \(¹⁷⁷Lu-Dotatate\) plus 

for patients with newly diagnosed high-grade 

best supportive care \(octreotide 30 mg long-acting repeatable 

Correspondence to: 

gastroenteropancreatic neuroendocrine tumours. These results 

Dr Simron Singh, University of 

\[LAR\]\) provided a significant increase in progression-free 

have clinical practice-changing implications and support the 

Toronto, Sunnybrook Odette 

survival to patients with progressive midgut grade 1–2 

Cancer Centre, Toronto, ON, 

use of ¹⁷⁷Lu-Dotatate earlier within the disease course of higher neuroendocrine tumours compared with patients treated with 

Canada 

grade 2–3 gastroenteropancreatic neuroendocrine tumours. 

high-dose octreotide 60 mg LAR and led to regulatory 

**simron.singh@sunnybrook.ca**

approvals for ¹⁷⁷Lu-Dotatate. 

See **Online** for appendix 1

analogues for almost all patients with low-grade and high-dose somatostatin analogues, targeted therapy, intermediate-grade \(grade 1–2\) gastroenteropancreatic radio ligand therapy, and local therapies, highlighting the NETs.6-8 Two phase 3, randomised, placebo-controlled need for robust, prospective, randomised data to inform trials \(CLARINET9 and PROMID10\) have established optimal treatment selection.14,15

somatostatin analogues as standard of care in grade 1–2 

We present the primary results of the ongoing phase 3 

NETs. The CLARINET study included patients with NETTER-2 trial, which aimed to investigate whether lower grade 2 NETs \(Ki67 <10%\), and excluded higher ¹⁷⁷Lu-Dotatate plus octreotide 30 mg LAR, at the same grade 2 NETs \(Ki67 ≥10%\).9 Historically, high-grade dose and schedule as established in the NETTER-1 trial,4 

neuroendocrine neoplasms were universally described as would prolong progression-free survival compared with poorly differentiated and often thought to be similar to high-dose octreotide 60 mg LAR, in patients with newly small-cell malignancies. In 2017, grade 3 well-differen-diagnosed, advanced higher grade 2–3, well-differentiated 

tiated NETs were formally recognised by WHO as a gastroenteropancreatic NETs. 

distinct entity from the poorly differentiated neuro-

endocrine carcinomas. There is a paucity of high-quality **Methods** evidence with respect to gastroenteropancreatic-NET **Study design and participants** treatments, especially for higher grade 2 \(Ki67 ≥10% and NETTER-2 was an international, multicentre, randomised, 

≤20%\) and grade 3 \(Ki67 >20% and ≤55%\) in the first-

parallel-group, superiority, open-label study done at 

line setting.11 In patients with Ki67 greater than 55%, the 45 centres in nine countries across North America, role of platinum-based therapy is generally accepted,12,13 Europe, and Asia. Eligible patients were aged 15 years or but no randomised phase 3 studies have yet investigated older with metastasised or locally advanced, histologically the most appropriate treatment strategy for these proven, higher grade 2 \(Ki67 ≥10% and ≤20%\) and grade 3 

patients.6,12 The lack of a defined first-line therapy \(Ki67 >20% and ≤55%\), well-differentiated gastro-represents an unmet need for these patients with enteropancreatic NETs that were considered inoperable metastatic disease. Retrospective analyses of treatment and had been diagnosed within 6 months before outcomes for patients with grade 3 well-differentiated screening. Histological confirmation and Ki67 assessment gastroenteropancreatic NETs have reported on various were done locally by each study site. Cytology was not an therapeutic strategies, including chemotherapy, acceptable method of gastroenteropancreatic-NET 

**2808 **

www.thelancet.com * ***Vol 403 June 29, 2024**

**Articles**

diagnosis in this study. Patients were required to have a progression were eligible for enrolment. Full eligibility Karnofsky Performance Scale score of at least 60, criteria are listed in the protocol \(appendix 2\). Patients See **Online** for appendix 2

bodyweight greater than 40 kg at screening, and self-reported sex data \(female or male\). All patients somatostatin receptor expression on all target lesions, provided written informed consent. 

assessed by any somatostatin receptor imaging modality, 

The trial protocol was approved by the institutional 

within 3 months before randomisation. Somatostatin review board or independent ethics committee at each receptor uptake was scored according to a visual semi-participating centre. The trial was done in accordance 

quantitative scale.16 Eligible patients were required to have with the principles of the Declaration of Helsinki, the an uptake score of 3 \(greater than liver but lower than International Conference on Harmonisation Good spleen\) or 4 \(greater than spleen\). We excluded patients Clinical Practice guidelines, and all applicable regulations. 

with creatinine clearance below 40 mL/min. Patients were The protocol, with amendments, is available in also ineligible if they had received any previous peptide appendix 2. No changes occurred to the methods after the receptor radionuclide therapy, hepatic artery embolisation, study commencement. NETTER-2 is registered with or radiofrequency ablation for gastroenteropancreatic ClinicalTrials.gov, NCT03972488. 

NETs. Previous systemic therapy for gastroenteropancreatic 

NETs was not allowed unless it was administered for less **Randomisation and masking** than 1 month and not within 12 weeks before We used interactive response technologies \(web and randomisation. Patients who had received short-term voice; Calyx, Nottingham, UK\) to randomly assign \(<6 months\) somatostatin analogues with no evidence of patients \(2:1\) to the ¹⁷⁷Lu-Dotatate group or control 261 patients screened

35 screen failures

226 randomly assigned

151 assigned to 177Lu-Dotatate

75 assigned to the control group

147 treated

73 treated 

78 still on treatment

15 still on treatment

69 ended treatment

58 ended treatment

42 disease progression

44 disease progression

13 clinician decision



7 clinician decision



6 adverse event



1 adverse event



4 death



4 death



3 informed consent 



2 informed consent 

withdrawal

withdrawal



1 other

4 not treated\*

8 re-treated

5 still on re-treatment

2 not treated†

29 crossed over

10 still on crossover

32 post-treatment follow-up

29 post-treatment follow-up

36 at the end of study

21 at the end of study

33 death

14 death



3 informed consent 



7 informed consent 

withdrawal

withdrawal

***Figure 1:***** Trial profile**

¹⁷⁷Lu-Dotatate=\[¹⁷⁷Lu\]Lu-DOTA-TATE. \*Reasons for not being treated were surgery before first treatment \(n=1\), randomisation mistake \(n=1\), informed consent withdrawal \(n=1\), and adverse event \(n=1\). †Reasons for not being treated were surgery before first treatment \(n=1\) and informed consent withdrawal \(n=1\). 

www.thelancet.com * ***Vol 403 June 29, 2024 **

**2809**

**Articles**

group stratified by tumour grade \(2 *vs* 3\) and tumour patient in a specific stratum was assigned the first origin \(pancreas *vs* other\). We chose a 2:1 randomisation randomisation entry from the randomisation schedule design to increase patients’ chances of receiving pre-allocated to that stratum. Subsequent patients in the ¹⁷⁷Lu-Dotatate. To minimise a potentially high dropout same stratum were assigned to the next available rate in the control group, patients were offered to cross randomisation entry from the randomisation schedule over to ¹⁷⁷Lu-Dotatate after centrally confirmed pre-allocated to that stratum. We used a block size of six radiological progression. The randomisation list within each stratum. Forced randomisation was not contained 240 pre-allocated records for each of the allowed in this study. Tumour grade and origin are both four strata in the study \(960 records in total\). The first important prognostic factors for gastro entero pancreatic NETs and thus were used as stratification factors.17,18 The 

**¹⁷⁷Lu-Dotatate plus High-dose **

**All patients **

trial was open label, so masking of treatments was not 

**octreotide 30 mg **

**octreotide 60 mg \(n=226\)**

applicable. 

**LAR \(n=151\)**

**LAR \(control **

**group; n=75\)**

**Procedures**

Age, years

61 \(51–72\)

60 \(51–69\)

61 \(51–70\)

Patients were randomly assigned to receive ¹⁷⁷Lu-Dotatate 

Sex

plus octreotide 30 mg LAR or high-dose octreotide 60 mg 

Male

81 \(54%\)

40 \(53%\)

121 \(54%\)

LAR \(control group; appendix 1 p 3\). In the ¹⁷⁷Lu-Dotatate 

Female

70 \(46%\)

35 \(47%\)

105 \(46%\)

group, four cycles of ¹⁷⁷Lu-Dotatate \(7·4 GBq \[200 mCi\]\) 

Race

were administered intravenously over 30 min every 

White

115 \(76%\)

50 \(67%\)

165 \(73%\)

8 weeks \(cumulative dose 29·6 GBq \[800 mCi\]\). For renal 

Asian

23 \(15%\)

11 \(15%\)

34 \(15%\)

protection, an intravenous infusion of 2·5% lysine-

American Indian or Alaska native

1 \(<1%\)

0

1 \(<1%\)

arginine amino acid solution was started 30 min before 

Black or African American

3 \(2%\)

2 \(3%\)

5 \(2%\)

¹⁷⁷Lu-Dotatate infusion and continued for 4 h.19 

Other

9 \(6%\)

12 \(16%\)

21 \(9%\)

Octreotide 30 mg LAR was administered intramuscularly 

Karnofsky Performance Scale score at baseline

after each ¹⁷⁷Lu-Dotatate infusion every 8 weeks until 

60

0

1 \(1%\)

1 \(<1%\)

completion of four ¹⁷⁷Lu-Dotatate cycles, and then every 

70–80

28 \(19%\)

10 \(13%\)

38 \(17%\)

4 weeks. In the control group, octreotide 60 mg LAR was 

90–100

123 \(81%\)

64 \(85%\)

187 \(83%\)

administered intramuscularly every 4 weeks. We assessed 

Time since initial diagnosis, months

1·8 \(1·2–3·7\)

2·1 \(1·4–3·9\)

1·9 \(1·3–3·7\)

tumours in both groups at baseline, week 16, and 

Primary tumour site

week 24, and then every 12 weeks until centrally 

Pancreas

82 \(54%\)

41 \(55%\)

123 \(54%\)

confirmed disease progression or death. Somatostatin 

Small intestine

45 \(30%\)

21 \(28%\)

66 \(29%\)

receptor imaging was not required for follow-up imaging. 

Rectum

7 \(5%\)

4 \(5%\)

11 \(5%\)

European Organisa tion for the Research and Treatment 

Stomach

6 \(4%\)

4 \(5%\)

10 \(4%\)

of Cancer Quality of Life Questionnaires \(EORTC 

Other

11 \(7%\)

5 \(7%\)

16 \(7%\)

QLQ-C30\) were completed by patients every 12 weeks 

Presence of metastases

from initiation of treatment until end of treatment. We 

Yes

150 \(99%\)

74 \(99%\)

224 \(99%\)

assessed safety throughout the trial, including adverse 

No

1 \(<1%\)

1 \(1%\)

2 \(<1%\)

events and laboratory toxicities \(graded according to the 

Site of metastases \(>10% patients\)

National Cancer Insti tute Common Terminology Criteria 

Bone

37 \(25%\)

18 \(24%\)

55 \(24%\)

for Adverse Events \[CTCAE\] version 5.0\). Randomised 

Liver

134 \(89%\)

69 \(92%\)

203 \(90%\)

treatment was allowed to continue until centrally 

confirmed disease progression or treatment 

Lymph nodes\*

101 \(67%\)

34 \(45%\)

135 \(60%\)

discontinuation for another reason. Patients with disease 

Peritoneum

26 \(17%\)

9 \(12%\)

35 \(15%\)

progression were able to enrol for post-progression 

Neuroendocrine tumour grade at diagnosis

crossover \(control group\) or re-treatment \(¹⁷⁷Lu-Dotatate 

Grade 2 \(Ki67 ≥10% and ≤20%\)

99 \(66%\)

48 \(64%\)

147 \(65%\)

group\) upon meeting protocol criteria. 

Grade 3 \(Ki67 >20% and ≤55%\)

52 \(34%\)

27 \(36%\)

79 \(35%\)

Ki67 index

17% \(12–25\)

16% \(12–25\)

16% \(12–25\)

**Outcomes**

Previous therapy with somatostatin 

24 \(16%\)

18 \(24%\)

42 \(19%\)

analogues†

The primary endpoint was progression-free survival, 

Highest somatostatin receptor tumour uptake score‡

defined as time from randomisation to first-line 

Score 3

56 \(37%\)

25 \(33%\)

81 \(36%\)

progression \(as assessed by independent blinded central 

review according to the Response Evaluation Criteria in 

Score 4

95 \(63%\)

50 \(67%\)

145 \(64%\)

Solid Tumours \[RECIST\] version 1.120\) or death from any 

Data are median \(IQR\) or n \(%\). LAR=long-acting repeatable. \*Distant plus regional combined. †Most patients who cause. Key secondary endpoints were objective response 

received previous therapy with somatostatin analogues received only a single dose. No patients had disease progression before study enrolment. ‡Based on local assessment. 

rate, defined as the rate of best overall response of 

complete or partial response \(as assessed by independent 

***Table 1:***** Baseline demographic and clinical characteristics \(full analysis set\)** central review according to RECIST 1.1\), and time to 

**2810 **

www.thelancet.com * ***Vol 403 June 29, 2024**

**Articles**

deterioration by 10 points from baseline in quality-of-life normal distribution to obtain the p value. We estimated \(QoL\) scores for global health status, diarrhoea, fatigue, the survival distribution of progression-free survival and pain as measured by EORTC QLQ-C30. Other using the Kaplan–Meier method. We estimated HRs secondary endpoints were disease control rate, duration with 95% CIs using a stratified Cox model. We compared of response, safety, and overall survival. The assessment objective response rate between treatment groups, and timing of patient outcomes corresponds to the schedule the corresponding odds ratio along with 95% CIs was described in the protocol \(appendix 2\). The NETTER-2 calculated using the stratified Cochran–Mantel–

study is ongoing for long-term patient follow-up and Haenszel method. We analysed time to deterioration in overall survival analysis. 

QoL using the same method as progression-free 

survival. Unless specified otherwise, we summarised 

**Statistical analysis**

categorical data as n \(%\) and continuous data as 

The statistical analysis plan is available in appendix 3. We median \(IQR\). 

See **Online** for appendix 3

did the primary analysis at 101 progression-free survival 

All safety analyses were done in the safety set, 

events as the final progression-free survival analysis. We which included all patients who received at least estimated that 99 progression-free survival events would one administration of study treatment, and patients were be required to achieve 90% power using a one-sided log-analysed according to the study treatment received. We 

rank test at the overall 2·5% level of significance, to detect summarised adverse events by number and percentage a 50% reduction in hazard rate, corresponding to a of patients having at least one adverse event by preferred doubling of median progression-free survival from an term using the Medical Dictionary for Regulatory assumed 15 months for the control group to 30 months Activities \(version 26.0\) and CTCAE \(version 5.0\). In the for the ¹⁷⁷Lu-Dotatate group. These assumptions were AE summary tables, patients with multiple CTCAE 

based on the results from NETTER-1 \(progression-free grades for the same preferred term were summarised survival was 28·4 months with ¹⁷⁷Lu-Dotatate\).19 We under the maximum CTCAE grade recorded for the conservatively selected a hazard ratio \(HR\) of 0·5 and, event. 

therefore, a progression-free survival of 15 months for 

control was used for the sample size calculations. **Role of the funding source** Assuming that enrolment would continue for The trial was designed and sponsored by Advanced approximately 22·2 months at a rate of ten patients per Accelerator Applications, a Novartis Company. Data were month and a 15% dropout rate by the time of primary analysed by the sponsor’s statistical team and provided to progression-free survival analysis, we estimated that all authors for interpretation. 

approximately 222 patients would need to be randomly 

assigned in a 2:1 ratio to the ¹⁷⁷Lu-Dotatate versus control **Results** groups. 

Between Jan 22, 2020, and Oct 13, 2022, we screened 

To control for the overall type I error, we tested the 261 patients, 35 \(13%\) of whom were excluded. We primary and key secondary endpoints hierarchically at randomly assigned 226 \(87%\) patients \(151 \[67%\] to the the time of the primary analysis. The order of the 

hypothesis testing was progression-free survival followed 

**¹⁷⁷Lu-Dotatate plus High-dose octreotide **

by objective response rate, time to deterioration in QoL 

**octreotide 30 mg **

**60 mg LAR **

by EORTC QLQ-C30 for global health scale, time to 

**LAR \(n=147\)**

**\(control group; n=73\)**

deterioration for diarrhoea, time to deterioration for 

**Duration of exposure, weeks**

fatigue, and time to deterioration for pain. An endpoint 

Any study treatment

71·1 \(47·9–100·0\)

40·3 \(21·0–64·1\)

would be tested only if all endpoints tested before it 

¹⁷⁷Lu-Dotatate

32·0 \(31·7–33·0\)

NA

showed statistical significance. 

Octreotide LAR

71·0 \(47·7–100·0\)

40·3 \(21·0–64·1\)

We used the full analysis set for efficacy analyses and 

**Number of ¹⁷⁷Lu-Dotatate cycles**

summary for demographic and baseline characteristics, 

1 cycle\*

1 \(<1%\)

NA

which comprised all randomly assigned patients, and 

2 cycles\*

10 \(7%\)

NA

patients were analysed according to the randomised 

3 cycles\*

7 \(5%\)

NA

treatment. All safety analyses were based on the safety 

4 cycles

129 \(88%\)

NA

set, which included all patients who received at least 

**Dose of ¹⁷⁷Lu-Dotatate**

one administration of study treatment. We compared 

Cumulative dose, GBq

29·2 \(28·0–29·8\)

NA

progression-free survival using a log-rank test stratified 

Dose per administration, 

7·3 \(7·2–7·5\)

NA

by randomisation stratification factors \(tumour grade 

GBq/cycle

and origin\). We calculated the rank statistic and its 

variance separately for each stratum, then calculated the 

Data are median \(IQR\) or n \(%\). LAR=long-acting repeatable. NA=not applicable. 

\*Reasons for not receiving all four cycles were disease progression \(n=11\), adverse final statistic as the sum of rank statistics from all four 

events \(n=4\), death \(n=2\), and informed consent withdrawal \(n=1\). 

strata divided by the square root of the sum of variances 

***Table 2:***** Treatment exposure in the randomised treatment period** from all four strata, and compared the result with the 

www.thelancet.com * ***Vol 403 June 29, 2024 **

**2811**

**Articles**

¹⁷⁷Lu-Dotatate group and 75 \[33%\] to the control group\), of patients, 121 \(54%\) patients were male, 105 \(46%\) were whom 147 \(97%\) in the ¹⁷⁷Lu-Dotatate group and female, and 165 \(73%\) were White \(table 1\). The primary 73 \(97%\) in the control group received at least one dose of tumour site was the pancreas in 123 \(54%\) patients and study treatment \(figure 1\). Of the 226 randomly assigned the small intestine in 66 \(29%\) patients; 147 \(65%\) patients **A**

100

177Lu-Dotatate group

55 events

Median progression-free survival 22·8 months \(95% CI 19·4–NE\)

Control group

46 events

80

Median progression-free survival 8·5 months \(95% CI 7·7–13·8\)

60

40

Progression-free survival \(%\)

20

HR 0·276 \(95% CI 0·182–0·418\); 

log-rank p<0·0001

0 0

2

4

6

8

10

12

14

16

18

20

22

24

26

28

30

32

34

36

Time since randomisation \(months\)

**Number at risk**

177Lu-Dotatate group 151

143

138

129

125

104

92

80

68

53

41

37

23

19

13

9

4

2

0

Control group

75

67

49

42

37

24

21

16

16

10

5

5

4

1

1

0

0

0

0

**B**

**177**

**HR \(95% CI\)**

**Lu-Dotatate**

**High-dose **

**plus octreotide**

**octreotide**

**30 mg LAR**

**60 mg LAR**

**\(n=151\)**

**\(control group; **

**n=75\)**

**Age, years**

<65 \(n=134\)

0·26 \(0·16–0·45\)

30/86 \(35%\)

30/48 \(63%\)

≥65 \(n=92\)

0·37 \(0·20–0·71\)

25/65 \(38%\)

16/27 \(59%\)

**Sex**

Female \(n=105\)

0·30 \(0·16–0·55\)

26/70 \(37%\)

19/35 \(54%\)

Male \(n=121\)

0·32 \(0·18–0·54\)

29/81 \(36%\)

27/40 \(68%\)

**Race**

White \(n=165\)

0·36 \(0·22–0·59\)

43/115 \(37%\)

27/50 \(54%\)

Asian \(n=34\)

0·14 \(0·05–0·38\)

10/23 \(43%\)

10/11 \(91%\)

**Tumour grade**

Grade 2 Ki67 ≥10% and ≤20% \(n=147\)

0·31 \(0·18–0·53\)

29/99 \(29%\)

25/48 \(52%\)

Grade 3 Ki67 >20% and ≤55% \(n=79\)

0·27 \(0·14–0·49\)

26/52 \(50%\)

21/27 \(78%\)

**Tumour origin**

Pancreas \(n=123\)

0·34 \(0·20–0·56\)

39/82 \(48%\)

27/41 \(66%\)

All non-pancreas \(n=103\)

0·23 \(0·12–0·46\)

16/69 \(23%\)

19/34 \(56%\)

Small intestine \(n=66\)

0·30 \(0·13–0·74\)

11/45 \(24%\)

10/21 \(48%\)

**Serum chromogranin A before randomisation**

≤2 × ULN \(n=67\)

0·22 \(0·09–0·49\)

11/43 \(26%\)

14/24 \(58%\)

>2 × ULN \(n=144\)

0·33 \(0·20–0·53\)

39/100 \(39%\)

28/44 \(64%\)

**Somatostatin receptor uptake per central review**

Score 3 \(n=34\)

0·31 \(0·10–0·89\)

9/24 \(38%\)

6/10 \(60%\)

Score 4 \(n=185\)

0·30 \(0·19–0·47\)

46/123 \(37%\)

38/62 \(61%\)

0·03125 0·0625 0·125

0·25

0·5

1

Favours 177Lu-Dotatate Favours control

***Figure 2:***** Progression-free survival \(full analysis set\)** \(A\) Kaplan–Meier curves for centrally assessed progression-free survival. \(B\) Subgroup analysis for progression-free survival based on central review and analysed by unstratified Cox model. HR=hazard ratio. LAR=long-acting repeatable. NE=not estimated. ULN=upper limit of normal as scored using the Common Terminology Criteria for Adverse Events. 

**2812 **

www.thelancet.com * ***Vol 403 June 29, 2024**

**Articles**

had grade 2 NETs and 79 \(35%\) had grade 3 NETs. responders in the control group. The disease control rate Two \(1%\) patients had locally advanced unresectable as assessed by central review was higher in the disease; the remaining 224 \(99%\) patients had distant ¹⁷⁷Lu-Dotatate group \(90·7% \[84·9–94·8\]\) compared with metastatic disease. Most patients had liver metastases the control group \(66·7% \[54·8–77·1\]\). 

\(203 patients \[90%\]\), followed by lymph node metastases 

Overall survival data were immature at the time of 

in 135 patients \(60%\), bone metastases in 55 patients \(24%\), primary progression-free survival analysis. Median and peritoneal metastases in 35 patients \(15%\). 

overall survival was not reached for either treatment 

Tumour somatostatin receptor uptake score was group, and we found no difference in overall survival 3 in 81 \(36%\) patients and 4 in 145 \(64%\) patients, as per between treatment groups at the time of follow-up. By the local assessment \(table 1\). The median time since initial cutoff date, 36 \(48%\) patients in the control group had diagnosis was 1·9 months \(IQR 1·3–3·7\). 

progressed and crossed over to ¹⁷⁷Lu-Dotatate treatment 

In total, 129 \(88%\) patients in the ¹⁷⁷Lu-Dotatate group \(n=29 during the crossover phase\) or received received all four cycles of ¹⁷⁷Lu-Dotatate \(table 2\). The ¹⁷⁷Lu-Dotatate or ¹⁷⁷Lu-Dotatoc \(n=7 during the follow-up median dose per cycle was 7·3 GBq \(IQR 7·2–7·5; phase\), which might have confounded the overall survival 198 mCi\), with a median cumulative dose of 29·2 GBq results in addition to the data immaturity. Overall survival \(28·0–29·8; 789 mCi; table 2\). Patients in the monitoring is ongoing in the long-term follow-up and ¹⁷⁷Lu-Dotatate group remained on study treatment will be analysed at the final analysis. 

\(¹⁷⁷Lu-Dotatate plus octreotide 30 mg LAR\) for a 

We found no significant difference between treatment 

median of 71·1** **weeks \(47·9–100·0\) compared with groups for the key secondary endpoint of time to 40·3 \(21·0–64·1\) weeks for the control group \(table 2\). At deterioration in QoL, as per EORTC QLQ-C30 scores the cutoff date of the primary analysis \(July 20, 2023\), \(appendix 1 p 4\). 

78 \(52%\) patients remained on study treatment in the 

Overall, 136 \(93%\) patients in the ¹⁷⁷Lu-Dotatate group 

¹⁷⁷Lu-Dotatate group and 15 \(20%\) remained on and 69 \(95%\) in the control group experienced an adverse octreotide 60 mg LAR in the control group. The median event in the randomised treatment period \(ie, up to the duration of patient follow-up from randomisation to data last randomised study treatment date plus 30 days\), with cutoff was 23·2 months \(16·4–28·8\). 

the most common \(≥20% in either group\) being nausea 

The study met its primary objective of progression-free \(40 \[27%\] *vs* 13 \[18%\]\), diarrhoea \(38 \[26%\] *vs* 25 \[34%\]\), survival. At data cutoff, progression-free survival events and abdominal pain \(26 \[18%\] *vs* 20 \[27%\]; table 4; had occurred in 55 \(36%\) patients in the ¹⁷⁷Lu-Dotatate appendix 1 p 5\). Adverse events of grade 3 or worse were group and 46 \(61%\) in the control group. The median observed in 52 \(35%\) patients in the ¹⁷⁷Lu-Dotatate group progression-free survival, as per blinded central assess-and 20 \(27%\) in the control group, with the most 

ment according to RECIST 1.1, was 22·8 months \(95% CI common \(>3% in either group\) being lymphocyte count 19·4–not estimated \[NE\]\) in the ¹⁷⁷Lu-Dotatate group decreased \(eight \[5%\] *vs* 0\), gamma-glutamyltransferase versus 8·5 months \(7·7–13·8\) in the control group. We increased \(seven \[5%\] *vs* two \[3%\]\), small intestinal found a reduction in the risk of disease progression or obstruction \(5 \[3%\] *vs* 0\), and abdominal pain death by around 72% in the ¹⁷⁷Lu-Dotatate group 

compared with the control group \(HR for progression-

free survival with ¹⁷⁷Lu-Dotatate *vs* control 0·276 

**¹⁷⁷Lu-Dotatate plus octreotide High-dose octreotide 60 mg **

**30 mg LAR \(n=151\)**

**LAR \(control group; n=75\)**

\[0·182–0·418\]; p<0·0001; figure 2A\). The progression-

free survival benefit observed in the ¹⁷⁷Lu-Dotatate group 

Best overall response

was consistent across all prespecified subgroups 

Complete response

8 \(5%\)

0

\(figure 2B\). Progression-free survival results based on 

Partial response

57 \(38%\)

7 \(9%\)

local tumour response assessment by investigators were 

Stable disease

72 \(48%\)

42 \(56%\)

in agreement with the centrally reviewed data \(median 

Non-complete response or 

0

1 \(1%\)

non-progressive disease

progression-free survival 22·6 months \[17·7–NE\] in the 

Progressive disease

8 \(5%\)

14 \(19%\)

¹⁷⁷Lu-Dotatate group and 8·2 months \[5·6–11·1\] in the 

Unknown\*

6 \(4%\)

11 \(15%\)

control group\). 

Objective response rate

65 \(43·0%; 95% CI 35·0–51·3\)

7 \(9·3%; 95% CI 3·8–18·3\)

The objective response rate was significantly higher in 

the ¹⁷⁷Lu-Dotatate group \(43·0% \[95% CI 35·0–51·3\]\) 

Stratified odds ratio \(95% CI\)

··

7·81 \(3·32–18·40\)

than in the control group \(9·3% \[3·8–18·3\]\)—ie, an 

Stratified one-sided p value

··

<0·0001

improvement of 33·7% \(23·4–44·0\) and a stratified odds 

Disease control rate

137 \(90·7%; 95% CI 84·9–94·8\) 50 \(66·7%; 95% CI 54·8–77·1\)

ratio of 7·81 \(3·32–18·40; p<0·0001; table 3\). 

Data are n \(%\) unless otherwise indicated. LAR=long-acting repeatable. \*In the 177Lu-Dotatate group, two patients had Eight \(5%\) patients in the ¹⁷⁷Lu-Dotatate group had a 

no valid post-baseline assessment and four patients had new anticancer therapy before post-baseline assessment. In the control group, six patients had no valid post-baseline assessments, three patients had new anticancer therapy complete response versus none in the control group 

before post-baseline assessment, and two patients had a scan with stable disease early after randomisation and started \(table 3\). The median duration of response was new anticancer therapy. 

23·3 months \(18·4–NE\) based on 65 responders in the 

***Table 3:***** Objective tumour response \(full analysis set\)** ¹⁷⁷Lu-Dotatate group and was NE \(2·3–NE\) with seven 

www.thelancet.com * ***Vol 403 June 29, 2024 **

**2813**

**Articles**

**¹⁷⁷Lu-Dotatate plus **

**High-dose octreotide **

**¹⁷⁷Lu-Dotatate plus **

**High-dose **

**octreotide 30 mg LAR **

**60 mg LAR \(control **

**octreotide 30 mg **

**octreotide 60 mg **

**\(n=147\)**

**group; n=73\)**

**LAR \(n=147\)**

**LAR \(control **

**group; n=73\)**

All grades

Grade ≥3

All grades

Grade ≥3

All grades Grade ≥3

All grades Grade ≥3

Adverse events

136 \(93%\)

52 \(35%\)

69 \(95%\)

20 \(27%\)

Immediate 

30 \(20%\)

20 \(14%\)

1 \(1%\)

1 \(1%\)

Related to any 

101 \(69%\)

23 \(16%\)

43 \(59%\)

3 \(4%\)

haematotoxicities\*

treatment

Anaemia

1 \(<1%\)

1 \(<1%\)

1 \(1%\)

1 \(1%\)

Related to 

96 \(65%\)

22 \(15%\)

NA

NA

¹⁷⁷Lu-Dotatate

Thrombocytopenia†

17 \(12%\)

3 \(2%\)

0

0

Related to 

55 \(37%\)

2 \(1%\)

43 \(59%\)

3 \(4%\)

Leukopenia‡

3 \(2%\)

3 \(2%\)

0

0

octreotide

Neutropenia§

3 \(2%\)

3 \(2%\)

0

0

Serious adverse 

30 \(20%\)

24 \(16%\)

15 \(21%\)

13 \(18%\)

Nephrotoxicities¶

13 \(9%\)

3 \(2%\)

4 \(5%\)

1 \(1%\)

events

Cardiovascular and 

11 \(7%\)

11 \(7%\)

10 \(14%\)

10 \(14%\)

Related to any 

8 \(5%\)

6 \(4%\)

1 \(1%\)

1 \(1%\)

electrolyte disorder||

treatment

Secondary 

1 \(<1%\)

1 \(<1%\)

0

0

Related to 

8 \(5%\)

6 \(4%\)

NA

NA

haematological 

¹⁷⁷Lu-Dotatate

malignancies

Related to 

0

0

1 \(1%\)

1 \(1%\)

Data are n \(%\). Table includes time from randomisation up to the last randomised octreotide

study treatment date plus 30 days. LAR=long-acting repeatable. 

Fatal serious 

3 \(2%\)

3 \(2%\)

2 \(3%\)

2 \(3%\)

MedDRA=Medical Dictionary for Regulatory Activities. \*The search included adverse events

Standardised MedDRA Query for grade ≥3 events under the following categories: Related to any 

0

0

0

0

granulocytosis, haematopoietic cytopenias affecting more than one type of blood treatment

cell, haematopoietic erythropenia, and haematopoietic leukopenia and for grade ≥2 events under the category of haematopoietic thrombocytopenia. 

Adverse events leading to discontinuation

†Includes preferred terms of platelet count decreased and thrombocytopenia. 

¹⁷⁷Lu-Dotatate

3 \(2%\)

1 \(<1%\)

NA

NA

‡Includes preferred terms of white blood cell count decreased and leukopenia. 

Octreotide

5 \(3%\)

3 \(2%\)

2 \(3%\)

2 \(3%\)

§Includes preferred terms of neutrophil count decreased and neutropenia. 

¶The search included Standardised MedDRA Query categories of acute renal Data are n \(%\). Table includes time from randomisation** **up to the last randomised failure, chronic kidney disease, and tubulointerstitial diseases of any grade and study treatment date plus 30 days. LAR=long-acting repeatable. NA=not any duration. ||Includes two grade 5 events. Both reported disease under study as applicable. 

primary reason for death \(dyspnoea \[n=1\] in the ¹⁷⁷Lu-Dotatate group and tumour lysis syndrome \[n=1\] in the control group\). 

***Table 4:***** Safety summary during the randomised treatment period** **\(safety set\)**

***Table 5:***** Adverse events of special interest during the randomised** **treatment period \(safety set\)**

\(four \[3%\] *vs* three \[4%\]; table 4; appendix 1 p 5\). Adverse events of special interest of CTCAE grade 3 or worse study of any therapy for patients with grade 3 well-occurred in three \(2%; leukopenia\), one \(<1%; anaemia\), differentiated gastroenteropancreatic NETs. In this and three \(2%; thrombocytopenia\) patients in study, patients with newly diagnosed higher grade 2–3, the ¹⁷⁷Lu-Dotatate group versus 0 \(leukopenia\), somatostatin receptor-positive, metastatic, gastroentero-one \(1%; anaemia\), and 0 \(thrombocytopenia\) in the pancreatic NETs were shown to significantly benefit control group \(table 5\). One case of myelodysplastic from radioligand therapy. The study met its primary syndrome was observed in the ¹⁷⁷Lu-Dotatate group by objective, with ¹⁷⁷Lu-Dotatate plus octreotide 30 mg LAR 

the time of data cutoff \(at approximately 14 months from reducing the risk of disease progression or death by the first dose\). 

around 72% compared with high-dose octreotide 60 mg 

Six deaths occurred during the randomised treatment LAR. Consistent benefit was observed across all period \(two in the ¹⁷⁷Lu-Dotatate group and four in the subgroups, including grade 2–3 NETs, and pancreatic as control group\), all attributed to disease progression under well as non-pancreatic primary origin. In this patient study. Discontinuation rates due to adverse events were population with grade 2–3 NETs, the objective response low for ¹⁷⁷Lu-Dotatate \(three \[2%\]\) and for octreotide LAR rate was 43·0% \(one of the highest reported in the \(five \[3%\] in the ¹⁷⁷Lu-Dotatate group and two \[3%\] for literature\) with ¹⁷⁷Lu-Dotatate plus octreotide 30 mg octreotide LAR in the control group; table 4\). Few patients LAR compared with 9·3% for octreotide 60 mg LAR. No required dose reduction \(three \[2%\] *vs* one \[1%\]\) and the new safety concerns were observed. Myelodysplastic frequency of dose interruptions was similar in both groups syndrome is a recognised risk of radioligand therapy \(23 \[16%\] *vs* 11 \[15%\]\). 

with ¹⁷⁷Lu-Dotatate.19,21 In this study, one case of 

myelodysplastic syndrome was observed in the 

**Discussion**

¹⁷⁷Lu-Dotatate group. However, the follow-up time was 

NETTER-2 is the first phase 3 study to report results for limited at the time of primary analysis; long-term safety radioligand therapy administered first line to patients in follow-up and data collection on secondary any cancer population. It is also the first randomised haematological malignancies are ongoing. 

**2814 **

www.thelancet.com * ***Vol 403 June 29, 2024**

**Articles**

Before this study, little evidence existed to support designed to be open label. Bias was mitigated through treatment decisions in this patient population, and the blinded central review of imaging data. Although this outcomes were generally poor. Although somatostatin study was open to patients aged 15 years or older, no analogues have been used as first-line treatment for accrual of adolescent patients aged 15–17 years occurred; advanced grade 1–2 gastroenteropancreatic NETs therefore, these data relate to adults only. Relative \(Ki67 <10%\) following the phase 3 PROMID10 and effectiveness to other available therapies, sequencing, CLARINET studies,9,22 such robust data do not exist for cost-effectiveness, and access issues should all be higher grade 2 tumours \(Ki67 ≥10%\) or grade 3 well-considered in future research. 

differentiated NETs.23 Small retrospective studies14,15,24,25 

Radioligand therapy is a promising new frontier in the 

have reported median progression-free survival treatment of cancers, which has previously been limited durations of 4–8 months in patients with grade 3 NETs to surgery and systemic therapy. Our results will help to treated with first-line somatostatin analogues. Other fill the evidence gap for high-grade gastroenteropancreatic potential options for higher grade 2–3 NETs include NETs that has been highlighted in treatment guidelines.6,12 

alkylating chemo 

therapy regimens, such as The significant improvement in progression-free survival 5-fluorouracil plus strepto zotocin and capecitabine plus and response with ¹⁷⁷Lu-Dotatate plus octreotide LAR 

temozolomide.8,15 Multicentre, retrospective analyses of compared with somatostatin analogues alone was temozolomide regimens for grade 3 NETs have shown observed across tumour site and grade and will have response rates between 27·3% and 51·0%.26,27 All of clinical practice-changing implications in support of these retrospective analyses were done after the design first-line radioligand therapy as standard of care for and initiation of NETTER-2, and complement the advanced higher grade 2 and grade 3, well-differentiated, evidence presented here to aid in treatment decisions gastroenteropancreatic NETs. 

for patients with higher grade 2 or 3 gastro-

**Contributors**

enteropancreatic NETs. Although there is no defined SS, PLK, IF, YZ, and WWdH were involved in the study design. SS, DH, standard of care and robust data for this patient SM, KH, BC, JC, AG-B, D-YO, IF, PA, WWdH, and DF vouch for the population, randomised data in patients with accuracy and integrity of the data. All authors were involved in data collection, had access to and contributed to the analysis or interpretation progressive pancreatic lower-grade NETs \(Ki67 cutoff of the data, and were involved in the writing, reviewing, and amending 

≤20%\) showed a response rate of 40% with capecitabine of the manuscript with the assistance of a medical writer funded by the plus temozolomide \(phase 2 ECOG-ACRIN E2211 sponsor. All authors approved the final draft and had final responsibility study\).28 The 60 mg dose of octreotide in the control for the decision to submit for publication. 

group was selected following the NETTER-1 study **Declaration of interests** design, which was developed following guidance from SS reports support for the present work from Novartis; grants or contracts from Novartis; consulting fees from Ipsen, Novartis, and the US Food and Drug Administration. The high dose Camurus; and meeting attendance support from Ipsen and Novartis. 

of octreotide did not have notable side-effects, DH reports support for the present work from Novartis; grants or suggesting that this regimen is well tolerated.4 contracts from Novartis, ITM, RayzeBio, Thermo Fisher Scientific, According to guidelines, 

Camurus, and Genentech/Roche; consulting fees from Novartis, 

6 somatostatin analogues may TerSera, ITM, Crinetics, Amryt, Camurus, Chimeric Therapeutics, be used in high-grade gastro enteropancreatic NETs, Harpoon Therapeutics, HarbourBioMed, Lantheus, Exelixis, and Ipsen; according to individual patient characteristics. Consider-and participation on a data safety monitoring board for Alphamedix. 

ing that all recruited patients in NETTER-2 had a high SM reports advisory board participation for Novartis Oncology and level of somatostatin receptor expression, this choice is Ipsen. KH reports payment for steering committee participation from Novartis; grants or contracts from Novartis and SOFIE Biosciences; rational. 

consulting fees from Advanced Accelerator Applications \(a Novartis In our study, time to deterioration in QoL was not company\), Amgen, AstraZeneca, Bain Capital, Bayer, Boston Scientific, significantly different between the treatment groups. Convergent, Curium, Debiopharm, EcoR1, Fusion, GE Healthcare, This finding is perhaps not surprising given that patients Immedica, ITM, Janssen, Merck, Molecular Partners, NVision, Pfizer, POINT Biopharma, Radiopharm Theranostics, Rhine Pharma, Siemens in both groups received a backbone of somatostatin Healthineers, SOFIE Biosciences, Telix, Theragnostics, and Y-mAbs; analogue therapy. Lack of QoL detriment with treatment honoraria from PeerVoice; meeting support from Janssen; advisory by a radioligand therapy compared with a generally well-board participation for Fusion and GE Healthcare; and stock or stock options for SOFIE Biosciences, Pharma15, NVision, Convergent, Aktis tolerated somatostatin analogue is encouraging. 

Oncology, and AdvanCell. MP reports grants or contracts from 

Until NETTER-2, no randomised studies had Advanced Accelerator Applications \(a Novartis company\), Novartis, investigated first-line radioligand therapy for any solid Ipsen, ITM, Camurus, and Boehringer Ingelheim; consulting fees from tumour. The data from NETTER-2 add to evidence that Advanced Accelerator Applications \(a Novartis company\), Novartis, Ipsen, Riemser, and HUTCHMED; honoraria from Ipsen, Advanced 

early molecular imaging could help optimise treatment Accelerator Applications \(a Novartis company\), Novartis, Boehringer selection and sequencing for patients with somato statin Ingelheim, MSD, Lilly, Recordati, Sanofi, and Serb; advisory board receptor-positive primary tumours of gastroentero-participation for Crinetics and Advanced Accelerator Applications pancreatic origin. 

\(a Novartis company\); and unpaid roles as ENETS committee member and President, on the ESMO education committee, and on the INCA Our study has some limitations. Because of differences advisory board. PLK reports grants or contracts from RayzeBio and in administration methods between treatments, and the Novartis; honoraria from Natera, ITM, BMS, and Foundation Medicine; need for radiation-exposure precautions, this study was steering committee participation \(uncompensated\) for RayzeBio and www.thelancet.com * ***Vol 403 June 29, 2024 **

**2815**

**Articles**

Exelixis; and advisory board participation and honoraria from Amgen, 5 

Strosberg JR, Caplin ME, Kunz PL, et al. 177Lu-Dotatate plus long-Genentech, Crinetics, HUTCHMED, and Ipsen. BC reports advisory acting octreotide versus high-dose long-acting octreotide in patients board participation and honoraria from Advanced Accelerator 

with midgut neuroendocrine tumours \(NETTER-1\): final overall 

Applications \(a Novartis company\). SL reports advisory board 

survival and long-term safety results from an open-label, 

participation for Advanced Accelerator Applications \(a Novartis randomised, controlled, phase 3 trial. *Lancet Oncol* 2021; company\). JC reports grants or contracts from Novartis, Pfizer, **22:** 1752–63. 

AstraZeneca, Advanced Accelerator Applications \(a Novartis company\), 6 

Del Rivero J, Perez K, Kennedy EB, et al. Systemic therapy for Eisai, Amgen, and Bayer; and consulting fees and honoraria from tumor control in metastatic well-differentiated 

gastroenteropancreatic neuroendocrine tumors: ASCO guideline. 

Novartis, Pfizer, Ipsen, Exelixis, Bayer, Eisai, Advanced Accelerator *J Clin Oncol* 2023; **41:** 5049–67. 

Applications \(a Novartis company\), Amgen, Sanofi, Lilly, Hutchinson 7 

Kos-Kudła B, Castaño JP, Denecke T, et al. European 

Pharma, ITM, Advanz, Merck, Esteve, and Roche. AG-B reports 

Neuroendocrine Tumour Society \(ENETS\) 2023 guidance paper for 

consulting fees from Advanced Accelerator Applications \(a Novartis nonfunctioning pancreatic neuroendocrine tumours. 

company\), Bayer, and Sanofi; and speaker fees and meeting support *J Neuroendocrinol* 2023; **35:** e13343. 

from Novartis. D-YO reports grants or contracts from AstraZeneca, 8 

Pavel M, Öberg K, Falconi M, et al. Gastroenteropancreatic 

Novartis, Array, Eli Lilly, Servier, BeiGene, MSD, and Handok; and neuroendocrine neoplasms: ESMO Clinical Practice Guidelines 

advisory board participation for AstraZeneca, Novartis, Genentech/

for diagnosis, treatment and follow-up. *Ann Oncol* 2020; Roche, Merck, Bayer, Taiho, ASLAN, Halozyme, Zymeworks, 

**31:** 844–60. 

BMS/Celgene, BeiGene, Basilea, Turning Point, Yuhan, Arcus 

9 

Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic Biosciences, IQVIA, MSD, LG Chem, Astellas, AbbVie, J-Pharma, 

enteropancreatic neuroendocrine tumors. *N Engl J Med* 2014; Mirati Therapeutics, Eutilex, Moderna, and Idience. CY reports grants **371:** 224–33. 

or contracts from Bayer, Ipsen, AstraZeneca, Boehringer Ingelheim, 10 Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-controlled, Servier, and Eisai; and honoraria from Bayer, Ipsen, MSD, Merck, double-blind, prospective, randomized study on the effect of 

Celgene, AstraZeneca, GSK, Eisai, Roche, Genentech, and Novartis. 

octreotide LAR in the control of tumor growth in patients with TRH reports consulting fees from TerSera; advisory board participation metastatic neuroendocrine midgut tumors: a report from the 

and research support from Camurus, ITM, Advanced Accelerator 

PROMID Study Group. *J Clin Oncol* 2009; **27:** 4656–63. 

Applications \(a Novartis company\), Crinetics, and Perspective 

11 Riechelmann RP, Taboada RG, de Jesus VHF, Iglesia M, 

Therapeutics; research support from Thermo Fisher Scientific; and an Trikalinos NA. Therapy sequencing in patients with advanced 

unpaid role as President of NANETS. IF, YZ, and PA report 

neuroendocrine neoplasms. *Am Soc Clin Oncol Educ Book* 2023; **43:** e389278. 

employment by Novartis and stock or stock options for Novartis. 

WWdH reports consulting fees and honoraria from Ipsen, Novartis, and 12 Eads JR, Halfdanarson TR, Asmis T, et al. Expert consensus practice recommendations of the North American Neuroendocrine Tumor 

Advanced Accelerator Applications \(a Novartis company\); and 

Society for the management of high grade gastroenteropancreatic consulting fees from ITM. DF reports grants or contracts from 

and gynecologic neuroendocrine neoplasms. *Endocr Relat Cancer* Camurus and Pfizer; honoraria from Novartis and Recordati Rare 2023; **30:** e220206. 

Diseases; and advisory board participation for Camurus, Ipsen, 13 Sorbye H, Welin S, Langer SW, et al. Predictive and prognostic Novartis, Recordati Rare Diseases, and Pfizer. All other authors declare factors for treatment and survival in 305 patients with advanced no competing interests. 

gastrointestinal neuroendocrine carcinoma \(WHO G3\): 

**Data sharing**

the NORDIC NEC study. *Ann Oncol* 2013; **24:** 152–60. 

Novartis is committed to sharing \(with qualified external researchers\) 14 Boutin M, Mathews A, Badesha J, et al. Well-differentiated grade 3 

access to patient-level data and supporting clinical documents from neuroendocrine tumors: characteristics, treatments, and 

outcomes from a population-based study. *Pancreas* 2022; eligible studies. This trial data availability is according to the criteria and **51:** 756–62. 

process described on https://www.clinicalstudydatarequest.com. These 15 de Mestier L, Lamarca A, Hernando J, et al. Treatment outcomes of requests are reviewed and approved by an independent review panel on advanced digestive well-differentiated grade 3 NETs. 

the basis of scientific merit. All data provided are anonymised to respect *Endocr Relat Cancer* 2021; **28:** 549–61. 

the privacy of patients who have participated in the trial in line with 16 Krenning EP, Valkema R, Kooij PP, et al. Scintigraphy and 

applicable laws and regulations. 

radionuclide therapy with \[indium-111-labelled-diethyl triamine **Acknowledgments**

penta-acetic acid-D-Phe1\]-octreotide. *Ital J Gastroenterol Hepatol* This study was funded by Advanced Accelerator Applications, a Novartis 1999; **31** \(suppl 2\)**:** S219–23. 

Company. We thank all patients and their families, research nurses, trial 17 Dasari A, Shen C, Halperin D, et al. Trends in the incidence, coordinators, nuclear medicine physicians, and operations staff for their prevalence, and survival outcomes in patients with 

neuroendocrine tumors in the United States. *JAMA Oncol* 2017; contributions, and the investigators \(a full list of investigators and staff **3:** 1335–42. 

can be found in appendix 1 p 2\). We are also grateful to Paola Santoro 18 Man D, Wu J, Shen Z, Zhu X. Prognosis of patients with 

for her contribution to the study design and its conduct and to neuroendocrine tumor: a SEER database analysis. *Cancer Manag Res* Germo Gericke for his contribution to the study design. Medical writing 2018; **10:** 5629–38. 

support \(including developing a draft outline and subsequent drafts in 19 Novartis. Lutathera prescribing information. Basel, Switzerland: consultation with the authors, assembling tables and figures, collating Novartis, 2023. https://www.novartis.com/us-en/sites/novartis\_us/

author comments, copyediting, fact checking, and referencing\) was files/lutathera.pdf \(accessed Dec 5, 2023\). 

provided by Jo Chapman at Aspire Scientific \(Bollington, UK\), and 20 Eisenhauer EA, Therasse P, Bogaerts J, et al. New response funded by Advanced Accelerator Applications, a Novartis Company. 

evaluation criteria in solid tumours: revised RECIST guideline **References**

\(version 1.1\). *Eur J Cancer* 2009; **45:** 228–47. 

1 

Sgouros G, Bodei L, McDevitt MR, Nedrow JR. 

21 European Medicines Agency. Lutathera: EPAR—product 

Radiopharmaceutical therapy in cancer: clinical advances and 

information. 2023. https://www.ema.europa.eu/en/documents/

challenges. *Nat Rev Drug Discov* 2020; **19:** 589–608. 

product-information/lutathera-epar-product-information\_en.pdf 

2 

de Jong M, Breeman WA, Bernard BF, et al. \[177Lu-DOTA0, Tyr3\] 

\(accessed March 13, 2024\). 

octreotate for somatostatin receptor-targeted radionuclide therapy. 

22 Caplin ME, Pavel M, Phan AT, et al. Lanreotide autogel/depot in *Int J Cancer* 2001; **92:** 628–33. 

advanced enteropancreatic neuroendocrine tumours: final results of 3 

Reubi JC, Schonbrunn A. Illuminating somatostatin analog action the CLARINET open-label extension study. *Endocrine* 2021; at neuroendocrine tumor receptors. *Trends Pharmacol Sci* 2013; **71:** 502–13. 

**34:** 676–88. 

23 Rindi G, Mete O, Uccella S, et al. Overview of the 2022 WHO 

4 

Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 

classification of neuroendocrine neoplasms. *Endocr Pathol* 2022; 177Lu-Dotatate for midgut neuroendocrine tumors. *N Engl J Med* **33:** 115–54. 

2017; **376:** 125–35. 

**2816 **

www.thelancet.com * ***Vol 403 June 29, 2024**

**Articles**

24 Lithgow K, Venkataraman H, Hughes S, et al. Well-differentiated 27 Chan DL, Bergsland EK, Chan JA, et al. Temozolomide in grade 3 

gastroenteropancreatic G3 NET: findings from a large single centre gastroenteropancreatic neuroendocrine neoplasms: a multicenter cohort. *Sci Rep* 2021; **11:** 17947. 

retrospective review. *Oncologist* 2021; **26:** 950–55. 

25 Merola E, Alonso Gordoa T, Zhang P, et al. Somatostatin analogs 28 Kunz PL, Graham NT, Catalano PJ, et al. Randomized study of for pancreatic neuroendocrine tumors: any benefit when Ki-67 is temozolomide or temozolomide and capecitabine in patients with 

≥10%? *Oncologist* 2021; **26:** 294–301. 

advanced pancreatic neuroendocrine tumors \(ECOG-ACRIN 

26 Apostolidis L, Dal Buono A, Merola E, et al. Multicenter analysis of E2211\). *J Clin Oncol* 2023; **41:** 1359–69. 

treatment outcomes for systemic therapy in well differentiated grade 3 neuroendocrine tumors \(NET G3\). *Cancers * 2021; **13:** 1936. 

www.thelancet.com * ***Vol 403 June 29, 2024 **

**2817**



# Document Outline

+ \[¹⁷⁷Lu\]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours \(NETTER-2\): an open-label, randomised, phase 3 study  
	+ Introduction 
	+ Methods  
		+ Study design and participants 
		+ Randomisation and masking 
		+ Procedures 
		+ Outcomes 
		+ Statistical analysis 
		+ Role of the funding source 

	+ Results 
	+ Discussion 
	+ Acknowledgments 
	+ References



